Skip to main content
SpringerLink
Log in

Tamoxifen and risk of large bowel cancer in women with breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background: The increasingly consistent association between estrogen replacement therapy and colorectal cancer suggests that the anti-estrogen tamoxifen may also be associated with large bowel cancer incidence.

Methods: Women with new diagnoses of breast cancer were identified from the Surveillance Epidemiology and End Results (SEER) Program, a set of geographically defined, population based cancer registries representing approximately ten percent of the U.S. population. Of 85,411 women with local or regional breast cancer diagnosed from 1983–90, 14,984 women were reported to have received hormonal therapy and 70,427 were not known to have received hormonal therapy. Subsequent cancer diagnoses were identified in this cohort beginning 6 months after initial breast cancer diagnosis until death, or December 31, 1994. Multivariate Cox proportional hazards models were used to estimate the risk of developing colorectal cancer and other second cancers according to hormonal therapy use.

Results: Over the follow-up period 793 colorectal, 2,648 contralateral breast, 506 endometrial, 250 ovarian, 98 gastric, and 1,765 other cancers were identified in the study cohort. While overall there was no association between hormonal therapy use and colorectal cancer (relative risk (RR) 1.09, 95% confidence interval (CI) 0.88–1.35), in the period five or more years after diagnosis, risk was increased significantly by about 50% (95% CI 1.00–2.15). As expected, based upon clinical trials data, cancers of the contralateral breast were significantly decreased, and cancers of the uterine endometrium were significantly increased. No other meaningful associations were observed. When women were excluded for whom hormonal therapy might represent therapy other than tamoxifen (premenopausal women and those who received chemotherapy), this did not meaningfully alter these estimates.

Conclusions: The results of this large population based cohort study suggest that tamoxifen therapy may modestly increase risk of large bowel cancer in women, but only after 5 years following initiation of breast cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McMichael AJ, Potter JD: Reproductions, endogenous and exogenous hormones and colon cancer: a review and hypothesis. J Natl Cancer Inst 65: 1201–1207, 1980

    Google Scholar 

  2. Potter JD: Hormones and colon cancer. J Natl Cancer Inst 87: 1039–1040, 1995

    Google Scholar 

  3. Calle EE: Hormone replacement therapy and colorectal cancer: interpreting the evidence. Cancer Causes Control 8: 127–129, 1997

    Google Scholar 

  4. Jacobs EJ, White E, Weiss NS: Exogenous hormones, reproductive history, and colon cancer. Cancer Causes Control 5: 359–366, 1994

    Google Scholar 

  5. Newcomb PA, Storer BE: Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 87: 1067–1071, 1995

    Google Scholar 

  6. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87: 517–523, 1995

    Google Scholar 

  7. Grodstein F, Martinez ME, Giovannucci E: Postmenopausal hormone use and colorectal cancer in the nurse's health study. Am J Epidemiol 143: 563, 1996

    Google Scholar 

  8. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S: Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control 8: 146–158, 1997

    Google Scholar 

  9. Potter JD, Slattery ML, Bostick RM, Gapstur SM: Colon cancer a review of the epidemiology. Epidemiol Rev 15: 499–545, 1993

    Google Scholar 

  10. Jordan VC: Tamoxifen and tumorigenicity: a predictable concern. J Natl Cancer Inst 87: 623–626, 1995

    Google Scholar 

  11. Bush TL, Helzlsouer KJ: Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial. Epidemiol Rev 15: 233–243, 1993

    Google Scholar 

  12. Fisher B, Constantino JP, Wickerman DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Ribidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiv E, Ford L, Wolmark N: J Natl Cancer Inst 90: 1371–1388, 1998

    Google Scholar 

  13. Love RR: Antiestrogens as chemopreventive agents in breast cancer: promise and issues in evaluation. Prev Med 18: 661–671, 1989

    Google Scholar 

  14. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127–205, 1984

    Google Scholar 

  15. Lerner LJ, Jordan VC: Development of antiestrogens and their use in breast cancer. Cancer Res 50: 4177–4189, 1990

    Google Scholar 

  16. Bilimona MM, Jordan VC, Morrow M: Activity in postmenopausal patients. In: Jordan VC (ed), Tamoxifen: a guide for clinicians and patients. PRR Inc., Huntington, NY, 1996, pp 75–88

    Google Scholar 

  17. Francavilla A, Di Leo A, Polimeno L, Conte D, Barone M, Fanizza G, Chiumarulo C, Rizzo G, Rubino M: Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding noncancerous colonic tissue. Gastroenterology 93: 1301–1306, 1987

    Google Scholar 

  18. McClendon JE, Appleby D, Claudon DB, Donegan WL, DeCosse JJ: Colonic neoplasms: tissue estrogen receptor and carcinoembryonic antigen. Arch Surg 112: 240–241, 1977

    Google Scholar 

  19. Meggouh F, Lointier P, Pezet D, Saez S: Status of sex steroid hormone receptors in large bowel cancer. Cancer 67: 1964–1970, 1991

    Google Scholar 

  20. Di Leo A, Linsalata M, Cavallini A, Messa C, Russo F: Sex steroid hormone receptors, epidermal growth factor receptor, and polyamines in human colorectal cancer. Dis Colon Rectum 35: 305–309, 1992

    Google Scholar 

  21. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645–651, 1995

    Google Scholar 

  22. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM: Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527–537, 1994

    Google Scholar 

  23. Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr: Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88: 832–834, 1996

    Google Scholar 

  24. Schoenberg BS, Greenberg RA, Eisenberg H: Occurrence of certain multiple primary cancers in females. J Natl Cancer Inst 43: 15–32, 1969

    Google Scholar 

  25. Kosary CL, Ries LAG, Miller BA, Harkey BF, Harras A, Edwards BK: SEER cancer statistics review, tables and graphs: 1973–1993. National Cancer Institute, Bethesda, MD, 1996

    Google Scholar 

  26. Cox DR: Regression models and life tables. J R Stat Soc [B] 34: 187–220, 1972

    Google Scholar 

  27. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR: Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87: 1359–1364, 1995

    Google Scholar 

  28. Sasco AJ, Chaplain G, Amoros E, Saez S: Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 7: 9–13, 1996

    Google Scholar 

  29. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, van den Belt-Dusebout AW, van Tinteren H: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448–452, 1994

    Google Scholar 

  30. Andersson M, Storm HH, Mouridsen HT: Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013–1017, 1991

    Google Scholar 

  31. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117–120, 1989

    Google Scholar 

  32. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cyto toxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1–15, 1992

    Google Scholar 

  33. Cook LS, Weiss NS, Potts M: Re: Second cancers after adjuvant tamoxifen therapy for breast cancer. [Letter]. J Natl Cancer Inst 89: 657, 1997

    Google Scholar 

  34. Rutqvist LE: Re: Second cancers after adjuvant tamoxifen therapy for breast cancer. [Letter]. J Natl Cancer Inst 88: 1497–1499, 1996

    Google Scholar 

  35. Han XL, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360–1363, 1992

    Google Scholar 

  36. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919–3924, 1993

    Google Scholar 

  37. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543–1549, 1996

    Google Scholar 

  38. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529–1542, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Polly A. Newcomb, Cam Solomon & Emily White

Authors
  1. Polly A. Newcomb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cam Solomon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emily White
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newcomb, P.A., Solomon, C. & White, E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 53, 271–277 (1999). https://doi.org/10.1023/A:1006117220284

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006117220284

Search

Navigation